Welcome to our dedicated page for IGC Pharma news (Ticker: IGC), a resource for investors and traders seeking the latest updates and insights on IGC Pharma stock.
IGC Pharma, Inc. (IGC) is at the forefront of developing innovative phytocannabinoid-based therapies aimed at treating a wide range of therapeutic indications. The company is involved in cutting-edge research to develop treatments for conditions such as neuropathic and cancer pain, epilepsy, and chronic neurological and oncological diagnoses, which can be life-altering or life-threatening. The mission of IGC Pharma is to alleviate pain, PTSD, seizures, cachexia, and other severe conditions through advanced cannabinoid-based formulations.
One of the primary focuses of IGC Pharma is to combat Alzheimer's disease. The company has developed two investigational drug assets, IGC-AD1 and TGR-63, that have shown potential in reducing key hallmarks of Alzheimer's, such as plaques and tangles, in cell line studies. IGC-AD1, a low-dose tetrahydrocannabinol-based formulation, is currently undergoing a Phase 2 clinical trial involving 146 participants to evaluate its efficacy in treating agitation in dementia due to Alzheimer's.
Beyond Alzheimer's treatment, IGC Pharma also addresses women's health through its wellness brand Holief, which provides relief for premenstrual syndrome and menstrual cramps. This diversified approach highlights the company’s commitment to improving quality of life across various patient demographics.
IGC Pharma's innovative research and development are complemented by strategic partnerships and a robust product portfolio, which collectively enhance its market presence and potential for growth.
IGC Pharma announced that CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a fireside chat hosted by Ascendiant Capital Markets on June 27, 2024, at 12:00 pm ET. They will discuss recent achievements and upcoming milestones. IGC Pharma focuses on developing treatments for Alzheimer's disease with a pipeline that includes five drug candidates. Notably, IGC-AD1 is in Phase 2 clinical trials targeting agitation in dementia associated with Alzheimer's, while other candidates like TGR-63, IGC-M3, and IGC-1C are in preclinical stages. The company also leverages AI for Alzheimer's research.
IGC Pharma announced a new study published in the European Society of Medicine Journal examining the impact of CYP2C9 genetic polymorphisms on the pharmacokinetics of delta-9-tetrahydrocannabinol (THC) in Alzheimer's patients. The study, conducted with Puerto Rican participants, revealed significant variations in THC metabolism among different genetic profiles, underscoring the importance of personalized medicine.
IGC is currently in Phase 2 trials of IGC-AD1, a THC-based drug candidate aimed at treating agitation in Alzheimer's patients. The research aligns with IGC's commitment to include underrepresented populations and develop innovative treatments. CEO Ram Mukunda and lead scientist Dr. Jagadeesh S. Rao highlighted the study's importance for personalized dosing strategies in Alzheimer's care.
IGC Pharma has commenced patient enrollment at Neurostudies in Port Charlotte, Florida, for its Phase 2 clinical trial of IGC-AD1, a THC-based formulation aimed at treating agitation in Alzheimer's patients. The trial, involving 146 participants, will assess the efficacy of IGC-AD1, which targets neuroinflammation and neurotransmitter imbalances. Neurostudies, led by Dr. Liliana Montoya and Dr. George Li, brings over 20 years of clinical research experience.
Two patients were enrolled in May 2024, marking a significant milestone for IGC Pharma. The company has 11 more trial sites under contract in the U.S. and Canada. Ram Mukunda, CEO of IGC Pharma, emphasized the company's commitment to advancing Alzheimer's therapies. IGC Pharma's pipeline includes five drug candidates aimed at different aspects of Alzheimer's pathology.
IGC Pharma will participate in the BIO International Convention at the San Diego Convention Center from June 3-6, 2024. The company intends to explore partnerships and strategic opportunities for its Alzheimer's disease therapies, including cannabinoid-based IGC-AD1 and amyloid-beta targeting TGR-63. IGC-AD1 is in Phase 2 clinical trials for agitation in dementia associated with Alzheimer’s, while TGR-63 aims to disrupt Alzheimer’s progression by targeting Aβ plaques. IGC Pharma's pipeline also includes IGC-M3 and IGC-1C, both in preclinical stages, focusing on Aβ plaques and tau protein, respectively. Additionally, the company leverages AI for research in Alzheimer's.
FAQ
What is the current stock price of IGC Pharma (IGC)?
What is the market cap of IGC Pharma (IGC)?
What is the main focus of IGC Pharma, Inc.?
What are IGC Pharma's key investigational drug assets for Alzheimer's?
What is the status of IGC-AD1?
Does IGC Pharma have products targeting women's health?
What conditions does IGC Pharma aim to treat with its therapies?
How does IGC Pharma contribute to Alzheimer's research?
What is the mission of IGC Pharma?
What is the significance of IGC's research on neuropathic and cancer pain?
Does IGC Pharma have any products in the wellness market?
What makes IGC Pharma unique in the biotech industry?
